



November 15, 2019

## PRODUCT SUPPLY UPDATE - ONCOLOGY

### **<sup>Pr</sup>FLUDARABINE PHOSPHATE FOR INJECTION, 25 mg/mL, DIN 02283859**

Dear Healthcare Provider,

Fludarabine phosphate for injection is indicated for second line treatment in patients with chronic lymphocytic leukemia (CLL) and low-grade non-Hodgkin's lymphoma (Lg-NHL) who have failed other conventional therapies (*Product Monograph, Teva Canada Limited, March 1, 2016*).

#### **CURRENT SUPPLY STATUS**

<b>Product</b>	<b>Current Supply</b>	<b>Allocation Filter in Place</b>	<b>Alternate Sources</b>
2 mL single use vial	Teva Warehouse: 15 weeks <b>NOW AVAILABLE</b>	Direct orders are individually assessed	Injectable: None Oral Tablets: <sup>Pr</sup> Fludara®

<sup>Pr</sup>Fludara® (fludarabine phosphate tablets 10 mg) is a registered trademark exclusively licensed to Genzyme Corporation (marketed by sanofi-aventis Canada Inc.)

Please check the **Health Canada Drug Shortages Website** for updates on this product.

#### **HOW TO ORDER – DIRECT FROM TEVA**

- Until supply stabilizes we will self-distribute
- Please email the following information to **Customer.Service@tevacanada.com**
  1. Your current inventory on hand
  2. Purchase order

Thank you for your understanding and continued support.

Sincerely,  
Hospital Division